Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-29

Clinical Trial Update: Safety Study of Oral Edaravone Administered in Subjects With ALS [Phase 3]

View source ↗

Summary

Phase 3 safety study of oral edaravone in people with amyotrophic lateral sclerosis has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • oral edaravone (edaravone)

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: ALS | Phase 3 | Status: COMPLETED | Results posted: 2022-08-29